New Advance to the Theranexus and BBDF Batten-1 Program for Juvenile Batten Disease (CLN3)

LYON, FRANCE and AUSTIN, TX / ACCESSWIRE / January 5, 2023 / Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons …